Nautilus Biotechnology, Inc.
No SEC Form 4 filings for $NAUT in the last 30 days.
See all $NAUT insider activity →Nautilus Biotechnology, Inc. (NAUT) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On September 11, 2026, Nautilus Biotechnology, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with TD Securities (USA), LLC (“TD Cowen”) to sell shares of the Company’s common stock, par value $0.0
Nautilus Data Technologies said its EcoCore Facility Cooling Distribution Unit was recognized by NVIDIA as NVIDIA-Validated AI Factory Infrastructure and listed on NVIDIA’s DSX Infrastructure Marketplace. The company cited testing results: over 4.1 MW (N-mode) and 3.2 MW (N+1), with 2°C ATD. The unit is water-source agnostic and available globally with 15-week delivery.
Nautilus Biotechnology, Inc. (NAUT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991-q2268xkearnings.htm EX-99.1 Document Exhibit 99.1 Nautilus Biotechnology Reports Second Quarter 2026 Financial Results SEATTLE, WA, July 28, 2026 – Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform,
Over the past 7 days, AlphAI's AI scored 1 news story mentioning NAUT (Nautilus Biotechnology, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent NAUT coverage spans financial news, corporate actions and insider activity.
Potential dilution and cash inflow from the ATM program could pressure the stock price short‑term while providing financing for growth.
NVIDIA validation and DSX listing can improve Nautilus’s credibility with hyperscalers, potentially supporting future orders but not a quantified financial impact here.
The 8-K provides fresh financial datapoints and a concrete roadmap realignment, which can reset near-term expectations for commercialization and cash burn.
Routine shareholder-meeting outcomes; no new operational or financial guidance, but it confirms governance decisions and auditor ratification.
Insider/10% owner selling can modestly pressure sentiment, but this Form 4 provides no new fundamental catalyst.
AlphAI scores every news story that mentions NAUT with an AI model for sentiment and relevance, and aggregates insider trades from Nautilus Biotechnology, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Nautilus Biotechnology, Inc. (NAUT) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On September 11, 2026, Nautilus Biotechnology, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with TD Securities (USA), LLC (“TD Cowen”) to sell shares of the Company’s common stock, par value $0.0
1 min readNautilus Data Technologies said its EcoCore Facility Cooling Distribution Unit was recognized by NVIDIA as NVIDIA-Validated AI Factory Infrastructure and listed on NVIDIA’s DSX Infrastructure Marketplace. The company cited testing results: over 4.1 MW (N-mode) and 3.2 MW (N+1), with 2°C ATD. The unit is water-source agnostic and available globally with 15-week delivery.
3 min readNautilus Biotechnology, Inc. (NAUT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991-q2268xkearnings.htm EX-99.1 Document Exhibit 99.1 Nautilus Biotechnology Reports Second Quarter 2026 Financial Results SEATTLE, WA, July 28, 2026 – Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform,
6 min readNautilus Biotechnology, Inc. (NAUT) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. naut-20260617 0001808805 FALSE 0001808805 2026-06-17 2026-06-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):
3 min readAH Equity Partners Bio II, L.L.C. sold 384,026 indirectly-held shares of Nautilus Biotechnology, Inc. (NAUT) at $2.35 ($0.90M total) on 2026-06-02.
2 min readAH Equity Partners Bio II, L.L.C. sold 4,615,974 indirectly-held shares of Nautilus Biotechnology, Inc. (NAUT) at $2.35 ($10.85M total) on 2026-06-02.
2 min readNautilus Biotechnology (NASDAQ: NAUT) reported its Q1 2026 financial results, highlighting progress towards commercialization through its Iterative Mapping Early Access Program and the appointment of a new VP of Global Sales. The company posted a net loss of $14.7 million, an improvement from the previous year, and ended the quarter with $143.4 million in cash, cash equivalents, and investments. Nautilus is set to host a conference call on April 28, 2026, to discuss these results further.
2 min readNautilus Biotechnology Inc. (NAUT) is highlighted as a promising life sciences penny stock due to its innovative proteomics technology. Baylor College of Medicine is the first customer of Nautilus's Iterative Mapping Early Access Program, utilizing the technology to address fundamental problems in cancer biology through a National Institutes of Health U01 grant. Nautilus's platform provides end-to-end solutions for quantifying the proteome, including reagents, consumables, optical imaging systems, and affinity reagents.
3 min read• Buck Institute's deployment of Nautilus' instrument generates tau proteoform data, providing external validation of the company's next-generation single-molecule proteomics platform • Joint research results show high reproducibility across sites and insight into novel tau biology, signaling a ...
2 min read• Buck Institute's deployment of Nautilus' instrument generates tau proteoform data, providing external validation of the company's next-generation single-molecule proteomics platform • Joint research results show high reproducibility across sites and insight into novel tau biology, signaling a ...
2 min read
